Ranbaxy has secured a highly lucrative out-of-court settlement with Pfizer that allows it to launch a generic version of Lipitor …
Cash-strapped governments and patent expiries fuel generics growth The increase in cost-limiting measures used by governments and a constant stream …
The new leader for the UK generics industry has promised to step up its bid to see more off-patent drugs …
Sanofi-Aventis and Bristol-Myers Squibb are feeling the heat from a Swiss drugs company which intends to market a generic version …
Pfizer’s pharmaceutical sales fell slightly last year, hit by patent expiries and difficult market conditions for its leading drug Lipitor. …
The entry of three generic competitors and the withdrawal of irritable bowel drug Zelnorm wiped billions off Novartis' revenues in …
Patients risk safety by taking biotech medicines that are similar but not the same as the branded drug, MPs have …
The UK pharmaceutical industry has announced plans to take legal action against the government over the way it controls how …
Some of Sanofi-Aventis' biggest selling drugs came under assault from generic competitors in the first part of 2007, holding back …
The global pharmaceutical industry has generally been seen as one of the most successful industries in delivering revenue growth with …
Some of the UK's top selling medicines are to be targeted in a new NHS drive to cut millions from …
A legal challenge to overturn Pfizer's UK patent on its top-selling cholesterol treatment has failed.Lipitor is the biggest selling drug …
Traditionally the US has been seen as the most attractive location for generics players with a combination of market fragmentation, …